Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A national registry-based study of ethnic differences in people with multiple sclerosis in Iran.
Ashtari F, Kavosh A, Baghbanian SM, Hosseini Nejad Mir N, Hosseini S, Razazian N, Majdinasab N, Farajzadegan Z, Shaygannejad V, Adibi I, Eskandarieh S, Sahraian MA. Ashtari F, et al. Among authors: baghbanian sm. Clin Neurol Neurosurg. 2024 Apr;239:108216. doi: 10.1016/j.clineuro.2024.108216. Epub 2024 Mar 2. Clin Neurol Neurosurg. 2024. PMID: 38490075
Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A national registry-based study.
Khodaie F, Moghadasi AN, Hosseinnataj A, Baghbanian SM, Ashtari F, Razazian N, Poursadeghfard M, Majdi-Nasab N, Hatamian H, Hoseini S, Nahayati MA, Nabavi SM, Faraji F, Harirchian MH, Mir NHN, Moghadam NB, Sharifipour E, Bayati A, Kamali H, Mozhdehipanah H, Jalali N, Abotorabi-Zarchi M, Kamyari N, Nikbakht R, Azimi A, Navardi S, Heidari H, Sahraian MA, Eskandarieh S. Khodaie F, et al. Among authors: baghbanian sm. Clin Neurol Neurosurg. 2024 Apr;239:108221. doi: 10.1016/j.clineuro.2024.108221. Epub 2024 Mar 2. Clin Neurol Neurosurg. 2024. PMID: 38447483
Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients with Multiple Sclerosis: A Phase IV, Post-marketing, Prospective, Multicenter Study.
Naser Moghadasi A, Ashtari F, Baghbanian SM, Shaygannejad V, Anjidani N, Ghadiri F, Sedighi B, Saeidi M, Amirifard H, Ayromlou H, Beladi Moghadam N, Ranjbar MB, Nazeri M, Niknam Z, Faraji F, Afsorde A, Sahraian MA. Naser Moghadasi A, et al. Among authors: baghbanian sm. Arch Iran Med. 2023 Nov 1;26(11):647-653. doi: 10.34172/aim.2023.95. Arch Iran Med. 2023. PMID: 38310425 Free PMC article. Clinical Trial.
Economic and Social Standing of Individuals in Iran Diagnosed with Multiple Sclerosis.
Ghadiri F, Sahraian MA, Ashtari F, Baghbanian SM, Majdi-Nasab N, Hatamian H, Faraji F, Bayati A, Sharifipour E, Jalali N, Mozhdehipanah H, Kamali H, Ayoubi S, Eskandarieh S, Naser Moghadasi A. Ghadiri F, et al. Among authors: baghbanian sm. Arch Iran Med. 2023 Aug 1;26(8):413-418. doi: 10.34172/aim.2023.63. Arch Iran Med. 2023. PMID: 38301102 Free PMC article.
Iranian specialists' approach to surgery in patients with multiple sclerosis.
Ghadiri F, Ebadi Z, Asadollahzadeh E, Sahraian MA, Azimi A, Navardi S, Heidari H, Abna Z, Aboutorabi M, Adibi I, Baghbanian SM, Paybast S, Poursadeghfard M, Hosseini S, Shahmohammadi S, Ghaffari M, Ghalyanchi-Langroodi H, Ghiasian M, Kamali H, Kouchaki E, Mahrabi F, Mohammadianinejad E, Nahayati MA, Moghadasi AN. Ghadiri F, et al. Among authors: baghbanian sm. Curr J Neurol. 2023 Apr 4;22(2):96-102. doi: 10.18502/cjn.v22i2.13336. Curr J Neurol. 2023. PMID: 38011379 Free PMC article.
Iranian specialists' approach to treatment escalation in multiple sclerosis patients with cognitive impairment.
Ghadiri F, Asadollahzadeh E, Ebadi Z, Sahraian MA, Azimi A, Navardi S, Heidari H, Abna Z, Aboutorabi M, Adibi I, Baghbanian SM, Paybast S, Poursadeghfard M, Hosseini S, Shahmohammadi S, Ghaffari M, Ghalyanchi-Langroodi H, Ghiasian M, Kamali H, Kouchaki E, Mahrabi F, Mohammadianinejad E, Nahayati MA, Moghadasi AN. Ghadiri F, et al. Among authors: baghbanian sm. Curr J Neurol. 2023 Jan 5;22(1):1-7. doi: 10.18502/cjn.v22i1.12610. Curr J Neurol. 2023. PMID: 38011357 Free PMC article.
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
Li Y, Saul A, Taylor B, Ponsonby AL, Simpson-Yap S, Blizzard L, Broadley S, Lechner-Scott J; Ausimmune/AusLong Investigators Group; Karabudak R, Patti F, Eichau S, Onofrj M, Ozakbas S, Horakova D, Kubala Havrdova E, Grand'Maison F, Alroughani R, Gerlach O, Amato MP, Altintas A, Girard M, Duquette P, Blanco Y, Ramo-Tello C, Laureys G, Kalincik T, Khoury SJ, Shaygannejad V, Etemadifar M, Singhal B, Mrabet S, Foschi M, Habek M, John N, Hughes S, McCombe P, Ampapa R, van der Walt A, Butzkueven H, de Gans K, McGuigan C, Oreja-Guevara C, Sa MJ, Petersen T, Al-Harbi T, Sempere AP, Van Wijmeersch B, Grigoriadis N, Prevost J, Gray O, Castillo-Triviño T, Macdonell R, Lugaresi A, Sajedi SA; MSBase; van der Mei I. Li Y, et al. J Neurol. 2024 Jan;271(1):472-485. doi: 10.1007/s00415-023-11980-z. Epub 2023 Sep 28. J Neurol. 2024. PMID: 37768389 Free PMC article.
Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study.
Abbasi Kasbi N, Ghadiri F, Sahraian MA, Nahayati MA, Moghadasi AN, Langroodi HG, Poursadeghfard M, Hosseini S, Heidari H, Baghbanian SM, Kamali H, Ameli Z, Shahmohammadi S, Navardi S. Abbasi Kasbi N, et al. Among authors: baghbanian sm. Acta Neurol Belg. 2024 Feb;124(1):205-212. doi: 10.1007/s13760-023-02366-z. Epub 2023 Sep 15. Acta Neurol Belg. 2024. PMID: 37715074 Clinical Trial.
57 results